Brii Biosciences Adds Us$100 Million To Advance Its Late-Stage Monoclonal Antibody Combination Therapy, Brii-196/Brii-198, For Non-Hospitalized Covid-19 Patients
Sep 07, 2021•almost 4 years ago
Amount Raised
$100 Million
Description
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced that the Company is committing an additional US$100 million to advance global regulatory filings and commercial efforts for its investigational SARS-CoV-2 (virus that causes COVID-19) combination therapy, BRII-196/BRII-198 ("combination BRII-196/BRII-198").
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech